Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
NCT03005184 · Vanderbilt University Medical Center · PHASE2 · withdrawn · last registry update 2018-01-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study is being redesigned and submitted as a new study.” | – | Registry record, Vanderbilt University Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AGTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-12-04Phase 3 first posted: Travere Therapeutics, Inc., sparsentan + irbesartan (NCT03762850)
- 2018-08-17Results posted on the registry: Vanderbilt University Medical Center, Angiotensin II (NCT00962949)
- 2018-06-12Phase 3 first posted: NHS Greater Glasgow and Clyde, sacubitril/valsartan + Valsartan (NCT03552575)
- 2018-04-10Phase 3 first posted: Travere Therapeutics, Inc., sparsentan + Irbesartan (NCT03493685)
- 2017-10-20Phase 3 first posted: University Hospital, Limoges, Valsartan + Placebo Oral Tablet (NCT03315832)
- 2017-05-24Phase 3 first posted: Second Xiangya Hospital of Central South University, Jinshuibao Capsule (NCT03164785)
- 2017-03-17Phase 3 first posted: Ludwig-Maximilians - University of Munich, Amlodipine + Losartan (NCT03082014)
- 2017-02-28Phase 3 first posted: Novartis Pharmaceuticals, sacubitril/valsartan + Enalapril (NCT03066804)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision